Can Shorter TB Prevention Regimens Work?

Randomized study evaluates efficacy, safety, and completion in high-risk patients

By
Julia Cipriano, MS, CMPP
March 23, 2026
4 min

Conexiant

Overview

A modified 3-month rifapentine plus isoniazid regimen was found to be noninferior to the standard 9-month isoniazid regimen for preventing tuberculosis in patients with rheumatic diseases and latent infection. The study demonstrated a favorable safety profile and similar treatment completion rates.

Background

Tuberculosis (TB) remains a significant global health concern, particularly among high-risk populations such as patients with rheumatic diseases. Traditional preventive regimens, such as the 9-month isoniazid treatment, can be burdensome and associated with adverse effects. Shorter regimens like the 3-month rifapentine plus isoniazid may offer a more effective and tolerable alternative, warranting investigation.

Data Highlights

Regimen	Cumulative TB Rate	Adverse Drug Reactions	Hepatotoxicity	Treatment Completion
3HP-PUMCH	0%	9.6%	4.4%	89.6%
9H	1.2%	15%	10.4%	91.2%

Key Findings

The 3-month rifapentine plus isoniazid regimen (3HP-PUMCH) showed a cumulative TB rate of 0% compared to 1.2% in the 9-month isoniazid regimen (9H).
Adverse drug reactions were reported in 9.6% of the 3HP-PUMCH group versus 15% in the 9H group.
Hepatotoxicity occurred in 4.4% of patients receiving 3HP-PUMCH, significantly lower than the 10.4% in the 9H group.
Treatment completion rates were similar, with 89.6% for 3HP-PUMCH and 91.2% for 9H.
The study was conducted with 536 patients aged 18 to 70 years with high-risk rheumatic diseases.
Further large-scale trials are needed to confirm these findings across diverse settings.

Clinical Implications

The findings suggest that the 3-month rifapentine plus isoniazid regimen may be a viable alternative to the standard 9-month regimen for TB prevention in patients with rheumatic diseases. This shorter regimen could reduce treatment burden and drug toxicity, potentially improving adherence and outcomes in this high-risk population.

Conclusion

The study provides high-level evidence supporting the use of a shorter TB preventive treatment regimen in patients with rheumatic diseases. Further research is necessary to validate these results and inform clinical guidelines.